Posts Archive

NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN

FDA approves Carfilzomib in combination with Dex or with Lenalidomide and Dex in replased Myeloma

NCT02960555: Phase 2 - Isatuximab in Patients With High Risk Smoldering Plasma Cell Myeloma

NCT02659293: Phase 3 - ATLAS Trial: Carfilzomib, Lenalidomide & Dex Vs Lenalidomide Alone After ASCT

NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM

NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM

NCI National Cancer Institute : What Are Clinical Trial Phases?

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors

NCT02963493: Phase 2 - Melphalan Flufenamide (Melflufen) With Dexamethasone in Relapsed MM (HORIZON)

NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation

NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM

NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma

NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM

NCT02765854: Phase 2: Ixazomib and Dex Vs Ixazomib, Dex and Lenalidomide, With NFKB2 Rearrangement

NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Cancer

NCT02951819: Phase 2 - Evaluate Dara-CyBorD in Previously Untreated and RRMM - LYRA

Cancer Research Institute: Immunotherapy & Chemotherapy: What's the Difference?

NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803